Minor Cannabinoids Getting Increased Market Attention
Beyond the major cannabinoids discussed throughout this publication, CBG and CBN represent minor cannabinoids increasingly featured in product formulations, each with distinct legal status considerations worth understanding clearly.
What CBG Is and Its Legal Status
Cannabigerol (CBG) is often called a precursor cannabinoid, since it converts into other cannabinoids (including THC and CBD) as the plant matures, meaning mature hemp plants typically contain relatively small amounts of CBG compared to CBD. CBG is non-intoxicating and generally treated similarly to CBD under the current hemp framework discussed throughout this publication, legal when derived from compliant hemp within the 0.3% total THC threshold.
What CBN Is and Its Legal Status
Cannabinol (CBN) forms primarily through the degradation of THC over time and exposure to light and air, rather than being directly synthesized by the plant in significant quantities. CBN is mildly intoxicating, less potent than THC, and its legal status generally follows the same naturally derived cannabinoid framework discussed throughout this publication, though its formation through degradation rather than direct plant synthesis has drawn some regulatory attention regarding whether specific production methods qualify as naturally derived.
Why Production Method Matters for Both Cannabinoids
CBG production considerations. Given naturally low CBG concentrations in mature plants, commercial CBG often comes from specially bred high-CBG hemp varieties or from extraction during earlier growth stages, both generally considered compliant naturally derived approaches, though documentation of the specific extraction and sourcing method remains important.
CBN production considerations. Since CBN typically forms through THC degradation, commercial CBN production sometimes involves accelerated degradation processes (heat, light exposure) applied to hemp-derived THC or CBD, raising similar naturally derived versus processed questions discussed in the Delta-8 content elsewhere in this publication.
What Buyers Should Verify
- Clear documentation of the specific hemp starting material and production method for both CBG and CBN products
- Total THC calculation on the finished product, since CBG and CBN products still need to demonstrate compliance with the overall THC threshold discussed throughout this publication
- Confirmation that any accelerated degradation process used for CBN production is documented and doesn't introduce other compliance concerns
Market Positioning for CBG and CBN Products
Both cannabinoids are increasingly marketed for specific effect profiles distinct from CBD or THC, CBG often positioned around focus and CBN around sleep support, though marketing claims should follow the same unsubstantiated health claim caution discussed throughout this publication regardless of which specific cannabinoid is featured.
Why This Matters for Product Development
As formulators increasingly explore minor cannabinoid positioning, understanding the specific compliance considerations for each cannabinoid, not just cannabinoids generally, supports more informed product development decisions.
Low Gravity Hemp supplies CBG and CBN with full documentation of starting materials and production methods. Contact us to talk through your minor cannabinoid formulation needs.
